{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:48:02Z","timestamp":1763142482389,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,13]]},"DOI":"10.7759\/cureus.92212","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:22:15Z","timestamp":1757769735000},"source":"Crossref","is-referenced-by-count":1,"title":["Optic Neuritis Following Nivolumab Treatment for Metastatic Melanoma: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Themis Gwendolyne","family":"Aguilar-Arciga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Chavira-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Antonio","family":"Mendoza-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ancona-Lezama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao B","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014, 16:589-93. 10.1093\/neuonc\/nou001","journal-title":"Neuro Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger AF","year":"2016","unstructured":"Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016, 29:806-12. 10.1097\/WCO.0000000000000391","journal-title":"Curr Opin Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171981","article-title":"Pembrolizumab-induced optic neuropathy - a case report","volume":"14","author":"Daetwyler E","year":"2023","unstructured":"Daetwyler E, Zippelius A, Meyer P, L\u00e4ubli H. Pembrolizumab-induced optic neuropathy - a case report. Front Immunol. 2023, 14:1171981. 10.3389\/fimmu.2023.1171981","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune checkpoint inhibitor-associated optic neuritis","volume":"127","author":"Francis JH","year":"2020","unstructured":"Francis JH, Jaben K, Santomasso BD, et al.. Immune checkpoint inhibitor-associated optic neuritis. Ophthalmology. 2020, 127:1585-9. 10.1016\/j.ophtha.2020.05.003","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens A","year":"2023","unstructured":"Martens A, Schauwvlieghe PP, Madoe A, Casteels I, Aspeslagh S. Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. J Ophthalmic Inflamm Infect. 2023, 13:5. 10.1186\/s12348-022-00321-2","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S31873","article-title":"Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma","volume":"4","author":"Andrews S","year":"2012","unstructured":"Andrews S, Holden R. Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res. 2012, 4:299-307. 10.2147\/CMAR.S31873","journal-title":"Cancer Manag Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JBAG","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat S","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al.. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016, 27:559-74. 10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000773","article-title":"Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors","volume":"7","author":"Nowosielski M","year":"2020","unstructured":"Nowosielski M, Di Pauli F, Iglseder S, et al.. Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2020, 7:e773. 10.1212\/NXI.0000000000000773","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/medicina54050082","article-title":"Bilateral optic neuritis secondary to nivolumab therapy: a case report","volume":"54","author":"Kartal \u00d6","year":"2018","unstructured":"Kartal \u00d6, Ata\u015f E. Bilateral optic neuritis secondary to nivolumab therapy: a case report. Medicina (Kaunas). 2018, 54:82. 10.3390\/medicina54050082","journal-title":"Medicina (Kaunas)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000909","article-title":"Photopsias in the setting of nivolumab therapy","volume":"41","author":"Ahluwalia A","year":"2021","unstructured":"Ahluwalia A, Kohli AA. Photopsias in the setting of nivolumab therapy. J Neuroophthalmol. 2021, 41:e25-6. 10.1097\/WNO.0000000000000909","journal-title":"J Neuroophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report","volume":"18","author":"Narumi Y","year":"2018","unstructured":"Narumi Y, Yoshida R, Minami Y, et al.. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer. 2018, 18:95. 10.1186\/s12885-018-3997-2","journal-title":"BMC Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372508-optic-neuritis-following-nivolumab-treatment-for-metastatic-melanoma-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:22:16Z","timestamp":1757769736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372508-optic-neuritis-following-nivolumab-treatment-for-metastatic-melanoma-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.92212","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,13]]}}}